Ionis Pharmaceuticals, Inc. (FRA:ISI)
Germany
· Delayed Price · Currency is EUR 69.82
-0.12 (-0.17%)
At close: Dec 4, 2025
Ionis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 966.96 | 705.14 | 787.65 | 587.37 | 810.46 | 729.26 | Upgrade
|
| Revenue Growth (YoY) | 20.41% | -10.47% | 34.10% | -27.53% | 11.13% | -35.04% | Upgrade
|
| Cost of Revenue | 893.25 | 912.75 | 908.76 | 847.26 | 654.3 | 11.95 | Upgrade
|
| Gross Profit | 73.71 | -207.61 | -121.11 | -259.9 | 156.16 | 717.32 | Upgrade
|
| Selling, General & Admin | 351.76 | 267.47 | 212.62 | 150.3 | 186.35 | 354.32 | Upgrade
|
| Research & Development | - | - | - | - | - | 535.08 | Upgrade
|
| Operating Expenses | 351.76 | 267.47 | 212.62 | 150.3 | 186.35 | 889.4 | Upgrade
|
| Operating Income | -278.05 | -475.08 | -333.73 | -410.19 | -30.19 | -172.08 | Upgrade
|
| Interest Expense | -90.72 | -90.45 | -81.46 | -8.12 | -9.35 | -9.51 | Upgrade
|
| Interest & Investment Income | 101.95 | 107.02 | 89.04 | 25.33 | 10.04 | 30.56 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.24 | 1.34 | 0.87 | -7.27 | -1.13 | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | -265.58 | -457.17 | -325.28 | -400.26 | -30.62 | -151.09 | Upgrade
|
| Gain (Loss) on Sale of Investments | 6.86 | -2.89 | -1.91 | -7.33 | 10.1 | 16.54 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0.16 | 149.6 | - | - | Upgrade
|
| Other Unusual Items | - | - | -6.61 | - | -8.63 | - | Upgrade
|
| Pretax Income | -258.72 | -460.07 | -333.97 | -257.99 | -29.15 | -134.55 | Upgrade
|
| Income Tax Expense | -2.38 | -6.17 | 32.32 | 11.74 | -0.55 | 345.19 | Upgrade
|
| Earnings From Continuing Operations | -256.34 | -453.9 | -366.29 | -269.72 | -28.6 | -479.74 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 35.48 | Upgrade
|
| Net Income | -256.34 | -453.9 | -366.29 | -269.72 | -28.6 | -444.26 | Upgrade
|
| Net Income to Common | -256.34 | -453.9 | -366.29 | -269.72 | -28.6 | -444.26 | Upgrade
|
| Shares Outstanding (Basic) | 159 | 150 | 143 | 142 | 141 | 140 | Upgrade
|
| Shares Outstanding (Diluted) | 159 | 150 | 143 | 142 | 141 | 140 | Upgrade
|
| Shares Change (YoY) | 8.89% | 4.42% | 0.95% | 0.59% | 1.01% | -8.85% | Upgrade
|
| EPS (Basic) | -1.61 | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 | Upgrade
|
| EPS (Diluted) | -1.61 | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 | Upgrade
|
| Free Cash Flow | -302.66 | -546.23 | -331.32 | -290.09 | 18.84 | 0.77 | Upgrade
|
| Free Cash Flow Per Share | -1.91 | -3.65 | -2.31 | -2.04 | 0.13 | 0.01 | Upgrade
|
| Gross Margin | 7.62% | -29.44% | -15.38% | -44.25% | 19.27% | 98.36% | Upgrade
|
| Operating Margin | -28.75% | -67.37% | -42.37% | -69.84% | -3.72% | -23.60% | Upgrade
|
| Profit Margin | -26.51% | -64.37% | -46.50% | -45.92% | -3.53% | -60.92% | Upgrade
|
| Free Cash Flow Margin | -31.30% | -77.46% | -42.06% | -49.39% | 2.33% | 0.11% | Upgrade
|
| EBITDA | -266.8 | -463.13 | -320.88 | -393.45 | -12.35 | -156.65 | Upgrade
|
| EBITDA Margin | -27.59% | -65.68% | -40.74% | -66.98% | -1.52% | -21.48% | Upgrade
|
| D&A For EBITDA | 11.25 | 11.95 | 12.85 | 16.74 | 17.84 | 15.43 | Upgrade
|
| EBIT | -278.05 | -475.08 | -333.73 | -410.19 | -30.19 | -172.08 | Upgrade
|
| EBIT Margin | -28.75% | -67.37% | -42.37% | -69.84% | -3.72% | -23.60% | Upgrade
|
| Revenue as Reported | 966.96 | 705.14 | 787.65 | 587.37 | 810.46 | 729.26 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.